Androgens: clinical research and therapeutics最新文献

{"title":"Impact of Testosterone Deficiency on Adipose Tissue Metabolic Activity and Plasma Lipoprotein and Glucose Homeostasis: The Role of Apolipoprotein E2 and E4 Isoforms","authors":"D. Karampela, P. Giannopoulou, A. Natsos, Nikolaos Margos, E. Zvintzou, Kyriakos E Kypreos","doi":"10.1089/andro.2022.0010","DOIUrl":"https://doi.org/10.1089/andro.2022.0010","url":null,"abstract":"","PeriodicalId":72197,"journal":{"name":"Androgens: clinical research and therapeutics","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81457585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examining Male Predominance of Severe COVID-19 Outcomes: A Systematic Review.","authors":"David K Twitchell,&nbsp;Michael B Christensen,&nbsp;Geoffrey Hackett,&nbsp;Abraham Morgentaler,&nbsp;Farid Saad,&nbsp;Alexander W Pastuszak","doi":"10.1089/andro.2022.0006","DOIUrl":"https://doi.org/10.1089/andro.2022.0006","url":null,"abstract":"<p><p>Although not universal, many epidemiological data sources signal that a higher proportion of males than females with confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections have adverse outcomes, such as intensive care unit (ICU) admission and death. Though likely multifactorial, the various hypotheses that have been proposed as underlying factors behind this trend are related to greater smoking prevalence among males, testosterone (T) deficiency causing an inflammatory storm, androgen-driven pathogenesis of SARS-CoV-2, a protective effect of estrogen in females, and inborn errors of cytokine immunity. This review aims at examining the evidence and at assessing the likelihood that the factors being investigated are contributory to the reported trend of male predominance of severe COVID-19 cases. Sources were obtained using the PubMed database and were selected based on their relevance to one of the primary hypotheses attempting to explain the strong male sex bias of severe SARS-CoV-2 infections. Emphasis was placed on meta-analyses and population-based studies. Sources are current through February 22, 2022. A severe COVID-19 case or outcome is defined in this review as a progression of the SARS-CoV-2 virus that results in either admission to an ICU for management of symptoms and clinical stabilization or which leads to death. Although the trend of male predominance of severe COVID-19 cases is likely multifactorial, the hypothesis of T deficiency causing an inflammatory storm has support from many studies with limited conflicting evidence. An inborn error in cytokine immunity is also well supported, but it needs more studies to add support to the hypothesis. The immunologic protective effect of estrogen is supported by multiple studies, but it also has conflicting evidence. It appears less likely that the trend is caused solely by an increased prevalence of smoking among males or an androgen-driven pathogenesis, based on the extent of conflicting evidence.</p>","PeriodicalId":72197,"journal":{"name":"Androgens: clinical research and therapeutics","volume":" ","pages":"41-53"},"PeriodicalIF":0.0,"publicationDate":"2022-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33489442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperandrogenism in Women with Polycystic Ovarian Syndrome: Pathophysiology and Controversies","authors":"Sarah Kanbour, A. Dobs","doi":"10.1089/andro.2021.0020","DOIUrl":"https://doi.org/10.1089/andro.2021.0020","url":null,"abstract":"","PeriodicalId":72197,"journal":{"name":"Androgens: clinical research and therapeutics","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85033801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Testosterone on Hospital Admission with COVID-19 Infection Is Associated with Increased Mortality","authors":"Mark Livingston, S. Ramachandran, Andrew J. Hartland, Aiden Plant, Michael Kirby, Geoffrey Hackett","doi":"10.1089/andro.2021.0029","DOIUrl":"https://doi.org/10.1089/andro.2021.0029","url":null,"abstract":"Objective: Males, despite equal sex-related susceptibility to COVID-19, appear at a greater risk of poor clinical outcomes and death. This suggests that serum testosterone could be a mediator. The aim of this retrospective study was to evaluate the association between serum total testosterone (TT), other prognostic indicators, and mortality in men with COVID-19. Methods: Of the 110 men consecutively admitted to Walsall Manor Hospital (with COVID-19 related symptoms) tested for SARS-CoV-2, 85 were positive and 27 of these men died. Serum TT was compared (rank-sum test) between men negative and positive for SARS-CoV-2, and this was followed by establishing factors associated with mortality in the latter group (rank-sum, logistic, Cox regression analyses). No patient was on testosterone therapy (TTh). Results: No significant difference (p = 0.12, rank-sum test) in serum TT between men positive [median TT (IQR) = 3.9 (1.9-7.22) nmol/L, 0 days (median) postadmission] and negative [median TT (IQR) = 5.9 (2.69-10.1) nmol/L, 2 days (median) postadmission] for SARS-CoV-2 was observed. Serum TT was lower (p = 0.0011, rank-sum test) in men with COVID-19 who died [median TT (IQR) = 2.0 (1.5-3.6) nmol/L] compared with survivors [median TT (IQR) = 5.0 (2.6-9.4) nmol/L]. Comorbidities obtained via medication history were not associated with mortality. Mortality (logistic regression) was associated with only age and serum TT (odds ratio: 0.77, 95% confidence intervals [CI]: 0.64-0.91). Survival (Cox regression) was inversely associated with serum TT (continuous variable, hazard ratio [HR]: 0.85) (95% CI: 0.74-0.98), stratified by median, TT ≥3.9 nmol/L (reference, TT <3.9 nmol/L), HR: 0.24 (95% CI: 0.089-0.63). Conclusions: Serum TT was inversely associated with mortality in men with COVID-19 and requires measurement at admission and while managing long COVID. Future research should establish whether low serum TT, possibly associated with negative acute phase response, contributes to poorer prognosis and a role for TTh. © Mark Livingston et al., 2022;Published by Mary Ann Liebert, Inc. 2022.","PeriodicalId":72197,"journal":{"name":"Androgens: clinical research and therapeutics","volume":"78 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80041269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Patterns of Use and Clinical Outcomes Between Injections of Testosterone Undecanoate and Testosterone Cypionate: An Electronic Health Record Cohort Study","authors":"A. Morgentaler, K. Lodaya, S. Telang, D. Hayashida, Yiqun Hu","doi":"10.1089/andro.2021.0024","DOIUrl":"https://doi.org/10.1089/andro.2021.0024","url":null,"abstract":"","PeriodicalId":72197,"journal":{"name":"Androgens: clinical research and therapeutics","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81794575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testosterone Therapy in Advanced Prostate Cancer.","authors":"Emily Chedrawe, Aditya Sathe, Josh White, Jesse Ory, Ranjith Ramasamy","doi":"10.1089/andro.2021.0035","DOIUrl":"10.1089/andro.2021.0035","url":null,"abstract":"<p><p>Androgen deprivation therapy is a mainstay of advanced prostate cancer (PCa) but the resulting low testosterone levels leave men susceptible to a multitude of adverse effects. These can include vasomotor symptoms, reduced sexual desire and performance, and mood changes. Testosterone therapy (TTh) in advanced PCa has historically been contraindicated since Huggins and Hodges reported that testosterone activates PCa. Although TTh has been demonstrated to be safe in patients who have undergone treatment for localized PCa, there is extremely limited evidence on its safety in advanced PCa. Despite the lack of evidence, some men with advanced PCa still inquire about TTh, and recent publications have described its use. In this article, we review the potential implications of TTh in men with advanced PCa, defined here as biochemical recurrence after localized therapy or metastatic PCa that is either hormone sensitive or castration resistant.</p>","PeriodicalId":72197,"journal":{"name":"Androgens: clinical research and therapeutics","volume":"3 1","pages":"180-186"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9166300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Androgen Therapy in Women with Testosterone Insufficiency: Looking Back and Looking Ahead","authors":"A. Traish, A. Morgentaler","doi":"10.1089/andro.2021.0030","DOIUrl":"https://doi.org/10.1089/andro.2021.0030","url":null,"abstract":"","PeriodicalId":72197,"journal":{"name":"Androgens: clinical research and therapeutics","volume":"45 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86994481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testosterone Therapy in Men with Klinefelter Syndrome: Analysis of a Global Federated Research Network.","authors":"Chase Carto,&nbsp;Justin Loloi,&nbsp;Katherine Campbell,&nbsp;Ranjith Ramasamy","doi":"10.1089/andro.2022.0020","DOIUrl":"https://doi.org/10.1089/andro.2022.0020","url":null,"abstract":"<p><strong>Introduction: </strong>The objective of this study was to determine the rates of hypogonadism and prescription of testosterone replacement therapy (TRT) in men with Klinefelter syndrome (KS). We hypothesized that men with KS are under-treated for testosterone deficiency with TRT due to a combination of factors, including a poor understanding of hypogonadism in this population and neurocognitive issues leading to delay in seeking of treatment for hypogonadism.</p><p><strong>Materials & methods: </strong>We queried TriNetX, a large multicenter electronic health record database, to identify all men with a diagnosis of KS (ICD-10-CM Q98.4). Prevalence of testosterone deficiency was determined as defined by testosterone level < 300 ng/dL. The primary outcome of the study was prescription of any of the following forms of TRT on the day of diagnosis or later.</p><p><strong>Results: </strong>There were in total 5437 men with diagnosis of KS. A total of 1581 men with KS received laboratory measurement of testosterone level, 1113 (70.4%) of whom were hypogonadal. Mean testosterone level in this group was 354 ng/dL [50-658]. Of the 1113 men found to be hypogonadal, only 657 (59.0%) men were given prescription for TRT.</p><p><strong>Discussion & conclusion: </strong>This is the first study to evaluate TRT prescribing habits in men with KS. In this large retrospective study, TRT was underprescribed in men with KS. Further studies are needed to corroborate these findings and to evaluate barriers to receiving care in this population.</p>","PeriodicalId":72197,"journal":{"name":"Androgens: clinical research and therapeutics","volume":"3 1","pages":"208-212"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10535900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypogonadotropic Hypogonadism in Diabesity: Pathogenic Factors and Therapeutic Implications.","authors":"Paresh Dandona,&nbsp;Sandeep Dhindsa,&nbsp;Husam Ghanim","doi":"10.1089/andro.2022.0019","DOIUrl":"https://doi.org/10.1089/andro.2022.0019","url":null,"abstract":"Hypogonadotropic hypogonadism (HH) was found to occur in 33% male patients with type 2 diabetes. 1 These patients had low total and free testosterone concentrations with inappropriately low or normal luteinizing hormone (LH) and follicle-stimulating hormone (FSH) concentrations. Since the occurrence of hypogonadism was not related to either HbA1c or the duration of diabetes but to body mass index (BMI), a study in nondiabetic obese patients was carried out, which revealed a prevalence of HH in 25%. 2 Thus, this is the commonest cause of hypogonadism in the community. These observations have added * 18 million hypogonadal patients in the United States alone, based on the prevalence of type 2 diabetes and obesity. In a study comparing type 1 and type 2 diabetic patients, it was shown that the occurrence of HH was confined to type 2 diabetes. 3 Since these observations were made in middle aged to older populations, a study in obese young males between 14 and 20 years of age was conducted. 4 These patients were found to have similar prevalence of HH as reflected in the total and free testosterone, LH, and FSH concentrations.","PeriodicalId":72197,"journal":{"name":"Androgens: clinical research and therapeutics","volume":"3 1","pages":"214-216"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10535901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effects of Testosterone on the Brain of Transgender Men.","authors":"Leire Zubiaurre-Elorza,&nbsp;Sebastian Cerdán,&nbsp;Carme Uribe,&nbsp;Carmen Pérez-Laso,&nbsp;Alberto Marcos,&nbsp;Ma Cruz Rodríguez Del Cerro,&nbsp;Rosa Fernandez,&nbsp;Eduardo Pásaro,&nbsp;Antonio Guillamon","doi":"10.1089/andro.2021.0008","DOIUrl":"https://doi.org/10.1089/andro.2021.0008","url":null,"abstract":"<p><p>Transgender men (TM) experience an incongruence between the female sex assigned when they were born and their self-perceived male identity. Some TM seek for a gender affirming hormone treatment (GAHT) to induce a somatic transition from female to male through continuous administration of testosterone. GAHT seems to be relatively safe. However, testosterone produces structural changes in the brain as detected by quantitative magnetic resonance imaging. Mainly, it induces an increase in cortical volume and thickness and subcortical structural volume probably due to the anabolic effects. Animal models, specifically developed to test the anabolic hypothesis, suggest that testosterone and estradiol, its aromatized metabolite, participate in the control of astrocyte water trafficking, thereby controlling brain volume.</p>","PeriodicalId":72197,"journal":{"name":"Androgens: clinical research and therapeutics","volume":"2 1","pages":"252-260"},"PeriodicalIF":0.0,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39693743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}